Syngulon

Rue Du Bois Saint Jean 15/1

4102 Seraing

BE

Syngulon

Foundation date

07/03/2013

Sector

#Biotechnology - other

Subsector

Syngulon is developing original genetic technologies to improve the efficiency of microorganisms.Syngulon has introduced a new genetic technology (US Patent 9,333,227, issued on May 10, 2016) for the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms.This issued patent is part of a new worldwide patent portfolio developed by Syngulon and available for licensing in all fields of use on a non-exclusive basis.  

Upcoming events

Latest news

  • Latest field trials validate strength of Biotalys’ first biocontrol Evoca

    Thursday May 19th 2022

  • Belgian biotech in European Top-3 despite turbulent times

    Wednesday May 18th 2022

  • KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus

    Wednesday May 18th 2022